IBDEI0HN ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7946,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,7946,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,7946,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,7947,0)
 ;;=L40.9^^39^391^294
 ;;^UTILITY(U,$J,358.3,7947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7947,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,7947,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,7947,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,7948,0)
 ;;=L50.9^^39^391^326
 ;;^UTILITY(U,$J,358.3,7948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7948,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,7948,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,7948,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,7949,0)
 ;;=L53.8^^39^391^150
 ;;^UTILITY(U,$J,358.3,7949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7949,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,7949,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,7949,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,7950,0)
 ;;=L53.9^^39^391^149
 ;;^UTILITY(U,$J,358.3,7950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7950,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,7950,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,7950,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,7951,0)
 ;;=L54.^^39^391^148
 ;;^UTILITY(U,$J,358.3,7951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7951,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,7951,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,7951,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,7952,0)
 ;;=L56.0^^39^391^142
 ;;^UTILITY(U,$J,358.3,7952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7952,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,7952,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,7952,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,7953,0)
 ;;=L56.1^^39^391^141
 ;;^UTILITY(U,$J,358.3,7953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7953,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,7953,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,7953,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,7954,0)
 ;;=L56.2^^39^391^274
 ;;^UTILITY(U,$J,358.3,7954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7954,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,7954,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,7954,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,7955,0)
 ;;=L56.3^^39^391^308
 ;;^UTILITY(U,$J,358.3,7955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7955,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,7955,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,7955,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,7956,0)
 ;;=L57.0^^39^391^13
 ;;^UTILITY(U,$J,358.3,7956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7956,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,7956,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,7956,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,7957,0)
 ;;=L60.0^^39^391^164
 ;;^UTILITY(U,$J,358.3,7957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7957,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,7957,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,7957,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,7958,0)
 ;;=L60.1^^39^391^272
 ;;^UTILITY(U,$J,358.3,7958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7958,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,7958,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,7958,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,7959,0)
 ;;=L60.2^^39^391^271
 ;;^UTILITY(U,$J,358.3,7959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7959,1,3,0)
 ;;=3^Onychogryphosis
